-
Dahlman Rose Reaffirms Uranerz Energy Buy, $5 PT
Wednesday, July 20, 2011 - 2:52pm | 102Dahlman Rose reaffirmed its Uranerz Energy (NYSE: URZ) Buy rating and $5 price target in a research report published today. In the report, Dahlman Rose states, "Uranerz announced that the US Nuclear Regulatory Commission (NRC) issued the Materials License for the Nichols Ranch in-situ recovery (...
-
The Cure for Cancer?
Wednesday, July 20, 2011 - 2:23pm | 722It is an exciting time to be in the field of cancer treatment as it appears that a cure for cancer could be just around the corner. According to an article from Seekibng Alpa, the biotechnology company Oncothyreon Inc. (NASDAQ: ONTY) has developed an immunotherapy cancer vaccine that has reached...
-
Puts Purchased on Affymax
Wednesday, July 20, 2011 - 1:00pm | 120Shares of Affymax (NASDAQ: AFFY) are lower on the session by 0.96%, currently trading at $7.25. The stock has been moving largely higher over the past four months and is currently trading above the 50-day moving average. Options traders are buying puts on the name today. A short while ago the...
-
Wednesday's Put/Call Ratio Leaders
Wednesday, July 20, 2011 - 12:55pm | 77Here are today's Put/Call Ratio leaders… 1. Vonage Holdings (NYSE: VG) 10,000 puts, 36 calls 2. Virgin Media (NASDAQ: VMED) 2,962 puts, 33 calls 3. Carnival Corp. (NYSE: CCL) 3,297 puts, 132 calls 4. Biosante Pharmaceuticals (NASDAQ: BPAX) 2,761 puts, 170 calls 5. FTI Consulting (NYSE: FCN) 4,319...
-
Biotech/Pharma Stocks Investor News Alert
Wednesday, July 20, 2011 - 11:57am | 1445Point Roberts, WA - July 20, 2011- Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for July 19, 2011. Biotech/Pharma Sector Snapshot Trading July 19 th Aethlon Medical (OTCBB: AEMD) traded lower by 0.0041...
-
Overlook this Sector and It Could Cost You
Wednesday, July 20, 2011 - 11:48am | 1019When President Obama's healthcare reform bill passed in late March 2010, name- brand pharmaceutical companies immediately scrambled. The timing could not have been worse. Most branded pharmaceutical...
-
Overlook this Sector and It Could Cost You
Wednesday, July 20, 2011 - 11:48am | 1019When President Obama's healthcare reform bill passed in late March 2010, name- brand pharmaceutical companies immediately scrambled. The timing could not have been worse. Most branded pharmaceutical...
-
Options Brief: BioSante Pharmaceuticals
Wednesday, July 20, 2011 - 10:38am | 72Shares of BioSante Pharmaceuticals (NASDAQ: BPAX) are lower on the session by 1.86%, trading at $3.64. Overall put volume is now running at 5.99x the daily average, with 60% of all puts traded being purchases on the offer. 2,611 contracts have traded on the session so far. BioSante...
-
Gilead's Investigational Antiretroviral Elvitegravir Once Daily Non-Inferior to Raltegravir Twice Daily at 48 Weeks
Wednesday, July 20, 2011 - 10:33am | 193Gilead Sciences, Inc. (Nasdaq: GILD) today announced Phase III clinical trial results from the pivotal Study 145 showing that its investigational antiretroviral elvitegravir, a novel oral integrase inhibitor being evaluated for the treatment of HIV-1 infection, was non-inferior to the integrase...
-
Morning Market Losers
Wednesday, July 20, 2011 - 10:07am | 129Dynavax Technologies Corporation (NASDAQ: DVAX) dipped 31.33% to $2.17 at 10:05 am. DVAX's cash, cash equivalents and marketable securities at June 30, 2011 came in at $61.7 million, versus $53.2 million at March 31, 2011. Icagen Inc (NASDAQ: ICGN) fell 23.10% to $5.96. Pfizer Inc (NYSE: PFE)...
-
Oncothyreon: Possible Pharma Blockbuster -Seeking Alpha
Wednesday, July 20, 2011 - 9:34am | 34Oncothyreon's (NASDAQ: ONTY) Stimuvax phase 3 trial very likely to be successful according to Seeking Alpha report.
-
Wedbush Initiates GTXI At Outperform, $13 PT
Wednesday, July 20, 2011 - 9:16am | 21Wedbush Securities has initiated GTx (NASDAQ: GTXI) at Outperform with a $13 price target.
-
Icagen Moving over 22% Lower after $6/Share Buyout Offer
Wednesday, July 20, 2011 - 9:11am | 241Pfizer Inc. (NYSE: PFE) and Icagen, Inc. (Nasdaq: ICGN) today announced that they have entered into a definitive merger agreement. Pfizer, which currently owns approximately 11% of Icagen's fully diluted shares, will acquire the remaining 8.3 million shares at a price of $6.00 per share. The...
-
Citi Updates On VRUS
Wednesday, July 20, 2011 - 9:07am | 88Citi has issued an update on Pharmasset Inc (NASDAQ: VRUS) and ther final cure rate from the ph2 study. According to the report, "Pharmasset just announced the final cure rate (SVR24) from the ph 2 study in 25 pts who have genotype 2/3 type of hepC virus. Recall this represents 25-35% of all hepC...
-
Pfizer To Acquire Icagen for $6/Share
Wednesday, July 20, 2011 - 8:30am | 346Pfizer Inc. (NYSE: PFE) and Icagen, Inc. (Nasdaq: ICGN) today announced that they have entered into a definitive merger agreement. Pfizer, which currently owns approximately 11% of Icagen's fully diluted shares, will acquire the remaining 8.3 million shares at a price of $6.00 per share. The...